Dr. Asha Mahajan, MD

Dr. Mahajan practices at Robert Wood Johnson Physician Enterprise in Somerset, New Jersey.

Dr. Mahajan's NPI, 1750776027, was assigned on April 2, 2015. Dr. Mahajan graduated from New York University School of Medicine in 2015. Dr. Mahajan holds New Jersey license 25MA11045000.

Dr. Mahajan's primary practice is Robert Wood Johnson Physician Enterprise, at 75 Veronica Ave, Somerset, NJ 08873 in Somerset County. The practice phone is (732) 369-5994.

Dr. Mahajan's primary practice is Robert Wood Johnson Physician Enterprise in Somerset, New Jersey. Dr. Mahajan is also affiliated with Robert Wood Johnson University Hospital. The medical group on file is Robert Wood Johnson Physician Enterprise. Dmand AI also links Dr. Mahajan to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mahajan practices, 2 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Mahajan's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Mahajan is licensed in New Jersey.

CMS data shows 1,659 Medicare services from Dr. Mahajan across 20 procedure codes in 2024, for 451 Medicare patients. Medicare paid $128,932 for them.

CMS counts 451 Medicare patients who saw Dr. Mahajan in 2024. The largest group is 65 to 74, with 162 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mahajan's median patient age at 67, with 55% women.

In 2024, Dr. Mahajan wrote 1,859 Medicare Part D claims for 280 patients. 88% of them were for generic drugs. CMS names the drug for 1,645 of them, across 26 drugs with 11 or more claims each, at $251,317 in total drug cost. In 2023, CMS named 1,489 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Mahajan for performance year 2024, reported through an alternative payment model (APM). Dr. Mahajan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mahajan as offering telehealth.

Dmand AI links 9 papers to Dr. Mahajan, published from 2016 to 2021. 2016 was the busiest year, with 3. The most frequent topics are Myocardial Infarction, Coronary Artery Disease and Percutaneous Coronary Intervention. Dr. Mahajan's most frequent co-authors are Nathaniel Rosso Smilowitz, MD, Martha Gulati, MD and Matthew Roe, MD.

CMS Open Payments shows 150 general payments to Dr. Mahajan from 26 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 92% of the total. Amgen Inc. paid the most, $512.

Dr. Mahajan graduated from New York University School of Medicine in 2015.